Cargando…

Risk factors for psychotic relapse in chronic schizophrenia after dose-reduction or discontinuation of antipsychotics. A systematic review and meta-analysis

INTRODUCTION: Patients are often treated with high doses or combinations of antipsychotics, which may hamper recovery. Dose-reduction (DR) or discontinuation of antipsychotic medication in chronic patients carries the risk of psychotic relapse. OBJECTIVES: To identify risk factors of psychotic relap...

Descripción completa

Detalles Bibliográficos
Autores principales: Bogers, J., Hambarian, G., Vermeulen, J., Dehaan, L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9475783/
http://dx.doi.org/10.1192/j.eurpsy.2021.1426
_version_ 1784789989077286912
author Bogers, J.
Hambarian, G.
Vermeulen, J.
Dehaan, L.
author_facet Bogers, J.
Hambarian, G.
Vermeulen, J.
Dehaan, L.
author_sort Bogers, J.
collection PubMed
description INTRODUCTION: Patients are often treated with high doses or combinations of antipsychotics, which may hamper recovery. Dose-reduction (DR) or discontinuation of antipsychotic medication in chronic patients carries the risk of psychotic relapse. OBJECTIVES: To identify risk factors of psychotic relapse after DR or discontinuation, we (i) determined the rate of relapse after DR or discontinuation in patients with chronic schizophrenia, and (ii) assessed risk factors for psychotic relapse. METHODS: From studies on dose-reduction from January 1950 through June 2019 we calculated event rates per person-years including 95% confidence intervals. We extracted: (1) patient characteristics (age, percentage of male subjects, setting, duration of illness), (2) dose-reduction/discontinuation characteristics (start-dose, end-dose, dose-reduction in milligrams and percentage of start-dose, time-period of dose-reduction), (3) follow-up characteristics (time after dose-reduction), and (4) study characteristics (blinding, publication-year and relapse definition). RESULTS: 46 unique cohorts, presenting 1677 patients in which doses were reduced/discontinued were included in meta-analysis. We found an overall event rate per person-years on psychotic relapse of 0.55 (CI95% 0.46-0.65;p<0.0001;I(2) =79). Most robust event rates for psychotic relapse were seen for discontinuing antipsychotics, and if not discontinuing, dose-reduction till under 5mg haloperidol equivalents daily (HE). Abrupt reduction yielded higher rates than gradual reduction. During short follow-up time more relapses occurred than in studies with long follow-up time. CONCLUSIONS: In patients with chronic schizophrenia discontinuing, and to a lesser extent DR till end-dose<5mgHE, patients who reduce doses abrupt, inpatients, and patients with a short duration of illness carry highest relapse risk. Most relapses occur during the first half year after DR.
format Online
Article
Text
id pubmed-9475783
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-94757832022-09-29 Risk factors for psychotic relapse in chronic schizophrenia after dose-reduction or discontinuation of antipsychotics. A systematic review and meta-analysis Bogers, J. Hambarian, G. Vermeulen, J. Dehaan, L. Eur Psychiatry Abstract INTRODUCTION: Patients are often treated with high doses or combinations of antipsychotics, which may hamper recovery. Dose-reduction (DR) or discontinuation of antipsychotic medication in chronic patients carries the risk of psychotic relapse. OBJECTIVES: To identify risk factors of psychotic relapse after DR or discontinuation, we (i) determined the rate of relapse after DR or discontinuation in patients with chronic schizophrenia, and (ii) assessed risk factors for psychotic relapse. METHODS: From studies on dose-reduction from January 1950 through June 2019 we calculated event rates per person-years including 95% confidence intervals. We extracted: (1) patient characteristics (age, percentage of male subjects, setting, duration of illness), (2) dose-reduction/discontinuation characteristics (start-dose, end-dose, dose-reduction in milligrams and percentage of start-dose, time-period of dose-reduction), (3) follow-up characteristics (time after dose-reduction), and (4) study characteristics (blinding, publication-year and relapse definition). RESULTS: 46 unique cohorts, presenting 1677 patients in which doses were reduced/discontinued were included in meta-analysis. We found an overall event rate per person-years on psychotic relapse of 0.55 (CI95% 0.46-0.65;p<0.0001;I(2) =79). Most robust event rates for psychotic relapse were seen for discontinuing antipsychotics, and if not discontinuing, dose-reduction till under 5mg haloperidol equivalents daily (HE). Abrupt reduction yielded higher rates than gradual reduction. During short follow-up time more relapses occurred than in studies with long follow-up time. CONCLUSIONS: In patients with chronic schizophrenia discontinuing, and to a lesser extent DR till end-dose<5mgHE, patients who reduce doses abrupt, inpatients, and patients with a short duration of illness carry highest relapse risk. Most relapses occur during the first half year after DR. Cambridge University Press 2021-08-13 /pmc/articles/PMC9475783/ http://dx.doi.org/10.1192/j.eurpsy.2021.1426 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Bogers, J.
Hambarian, G.
Vermeulen, J.
Dehaan, L.
Risk factors for psychotic relapse in chronic schizophrenia after dose-reduction or discontinuation of antipsychotics. A systematic review and meta-analysis
title Risk factors for psychotic relapse in chronic schizophrenia after dose-reduction or discontinuation of antipsychotics. A systematic review and meta-analysis
title_full Risk factors for psychotic relapse in chronic schizophrenia after dose-reduction or discontinuation of antipsychotics. A systematic review and meta-analysis
title_fullStr Risk factors for psychotic relapse in chronic schizophrenia after dose-reduction or discontinuation of antipsychotics. A systematic review and meta-analysis
title_full_unstemmed Risk factors for psychotic relapse in chronic schizophrenia after dose-reduction or discontinuation of antipsychotics. A systematic review and meta-analysis
title_short Risk factors for psychotic relapse in chronic schizophrenia after dose-reduction or discontinuation of antipsychotics. A systematic review and meta-analysis
title_sort risk factors for psychotic relapse in chronic schizophrenia after dose-reduction or discontinuation of antipsychotics. a systematic review and meta-analysis
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9475783/
http://dx.doi.org/10.1192/j.eurpsy.2021.1426
work_keys_str_mv AT bogersj riskfactorsforpsychoticrelapseinchronicschizophreniaafterdosereductionordiscontinuationofantipsychoticsasystematicreviewandmetaanalysis
AT hambariang riskfactorsforpsychoticrelapseinchronicschizophreniaafterdosereductionordiscontinuationofantipsychoticsasystematicreviewandmetaanalysis
AT vermeulenj riskfactorsforpsychoticrelapseinchronicschizophreniaafterdosereductionordiscontinuationofantipsychoticsasystematicreviewandmetaanalysis
AT dehaanl riskfactorsforpsychoticrelapseinchronicschizophreniaafterdosereductionordiscontinuationofantipsychoticsasystematicreviewandmetaanalysis